Ascendis Pharma AS (NAS:ASND)
$ 151.26 -2.17 (-1.41%) Market Cap: 8.67 Bil Enterprise Value: 9.12 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Ascendis Pharma A/S at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 08:00PM GMT
Release Date Price: $116.18 (-0.58%)
Jessica Macomber Fye
JPMorgan Chase & Co, Research Division - Analyst

Great. Good afternoon, everyone. My name is Jess Fye. I'm a senior biotech analyst at JPMorgan. And we're continuing the 40th Annual Healthcare Conference today with Ascendis.

I'm joined by the company's CEO, Jan Mikkelsen, who's going to give a presentation, and then we're go into some Q&A. If you want to ask a question for the Q&A, you can click the blue, "ask a question" button on your screen, that will send it to me, and I can ask the management those questions after they present.

So with that, let me turn it over to Jan.

Jan Moller Mikkelsen;S;President
Ascendis Pharma A;CEO, Member of Executive Board & Executive Director

/- -

Thank you, Jess. It's always a pleasure to be here. Going to Slide #2. Today, I will be making some forward-looking statement. Please refer to the Risk Factors section of our most recent annual report Form 20-F, and our SEC filings for a list of factors that can cause actual results to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot